Biostage raises $5.1M in private placement to advance esophageal implant clinical trial

Harvard Apparatus Regenerative Technology, Inc.

Raised ~$5.1M from new and existing investors via 854,771 shares and warrants for 427,390 shares at $5.92/unit.
Warrants exercisable at $8.88/share for 5 years; $4.8M received, $260K expected shortly.
Proceeds to accelerate FDA-approved 10-patient Phase 1/2 trial of Biostage Esophageal Implant for severe esophageal disease.
Company also developing Biostage Bronchial Implant for lung cancer and birth defects.
CEO David Green expressed optimism about advancing pipeline for patients and shareholders.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.